Main navigation

HM4: Assessing the value of innovative therapies: trends, challenges and learnings

By 2022-12-05T00:18:00

5M4A9983_TOPRA Symposium 2022_Day 1_20221017

This session focused on the evolution of the European Medicines Agency (EMA) and The European Network for Health Technology Assessment (EUnetHTA) collaboration.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

Not a TOPRA member yet? 

Join now to get access to:

  • Features and specialist articles
  • CPD supplements
  • Comprehensive archive

Become a member today!

Not sure yet?  Read one of our free editorials to see what you’re missing out on!